The Middle East and Africa HPV vaccine market size was valued at USD 0.095 billion in 2022. The HPV vaccine industry is anticipated to expand from USD 0.09 Billion in 2023 to USD 0.13 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.80% during the forecast period (2024 - 2032).The increasing initiatives by government & private organizations for early screening & vaccination, the rising prevalence of HPV-related diseases, and the approval of new HPV vaccines are major market drivers driving the HPV vaccines market in the Middle East and Africa.
Source: Secondary Research, MRFR Database, Primary Research, and Analyst Review
The Middle East and Africa HPV vaccines market CAGR is expanding due to the efficacy and protection provided by HPV vaccines to reduce the adverse effects associated with such infections. As manufacturers have developed novel immunization vaccines over the past years, a change in vaccination policies and beliefs has been observed worldwide. This has potentially increased the uptake and acceptability of HPV vaccines. Both bivalent and polyvalent vaccines have proved their efficacy and safety through clinical trials in protecting against HPV infections and cancer.
Furthermore, increasing cases of Human Papillomavirus (HPV) diseases drive HPV vaccine market revenue. The region faces a rising burden of HPV-related cancers and infections. Efforts to address the growing awareness of HPV's role in cervical and other cancers propel vaccination initiatives. Government-led immunization programs, improved healthcare infrastructure, and rising awareness contribute to higher vaccine uptake. Collaborations between healthcare organizations and vaccine manufacturers aim to combat HPV-related diseases, emphasizing prevention through vaccination. Despite challenges, the MEA HPV Vaccines Market reflects a commitment to public health, aiming to curb the prevalence of HPV infections and associated diseases in the region.
The Middle East and Africa HPV vaccines market segmentation, based on the vaccine type, includes quadrivalent HPV vaccines, bivalent HPV vaccines, and nonavalent HPV vaccines. The bivalent HPV vaccines segment dominated the market due to the growing awareness of cervical cancer prevention and vaccination initiatives. Public health campaigns, rising incidences of HPV-related cancers, and government efforts to expand vaccination programs contribute to increased demand. The efficacy and preventive benefits of bivalent HPV vaccines against certain high-risk HPV types underscore their importance in regional immunization strategies, fostering regional market growth.
Figure 1: Middle East and Africa HPV Vaccines Market, by Vaccine Type, 2023 & 2032 (USD Billion)
Source: MRFR Database, Secondary Research, Primary Research, and Analyst Review
The Middle East and Africa HPV vaccine market segmentation, based on the target population, includes girls & women and boys & men. The girls & women segment dominated the market due to the increasing awareness, governmental vaccination programs, and healthcare campaigns aimed to protect females from Human Papillomavirus (HPV) infections, a leading cause of cervical cancer. Efforts to reduce the incidence of cervical cancer in the region, along with advocacy for routine HPV vaccination, underscore the importance of immunization, contributing to the growth of the market.
The Middle East and Africa HPV vaccine market segmentation, based on end-users, includes hospitals, clinics, doctors’ offices, and schools. The hospital segment dominated the market due to the increased awareness and vaccination programs supported by hospitals. Efforts to prevent cervical cancer, a major concern, promote HPV vaccination. Collaborations between healthcare institutions and government initiatives are pivotal in expanding vaccine coverage. The rising understanding of HPV-related health risks and the focus on preventive healthcare contribute to hospitals driving the adoption of HPV vaccines in the Middle East and Africa.
The Middle East and Africa HPV vaccines market thrives due to increasing awareness of cervical cancer prevention, rising healthcare infrastructure, and government initiatives to combat HPV-related diseases. Efforts to address the burden of cervical cancer, coupled with growing vaccination campaigns, fuel market growth. The prevalence of HPV-related infections and associated cancers underscores the importance of vaccination. Collaborations between healthcare organizations and pharmaceutical companies to expand vaccination programs further contribute. As the region focuses on preventive healthcare, the HPV vaccine market experiences heightened demand, reflecting a proactive approach toward reducing the incidence of HPV infections and related cancers in the Middle East and Africa.
Figure 2: MIDDLE EAST AND AFRICA HPV VACCINES MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Leading market participants invest heavily in research and development to extend their product lines, allowing the HPV vaccine market to grow even more. Market participants are also undertaking numerous strategic activities to extend their footprint, with significant market outcomes including new product expansions, contractual agreements, mergers and acquisitions, more elevated investments, and collaboration with other organizations. The HPV vaccine industry must offer cost-effective items to enhance and survive in a more competitive, expanding market climate.
Major Participants in the HPV vaccines market are attempting to expand market needs by investing in research and development operations, including Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc, Sanofi S.A., Bharat Biotech, Inovio Pharmaceuticals, Inc., and Xenetic Biosciences, Inc.
Key participants in the HPV vaccine market include
Johnson & Johnson
Merck & Co., Inc.
AstraZeneca Plc
Serum Institute of India Pvt. Ltd.
Sanofi S.A.
Bharat Biotech
Inovio Pharmaceuticals, Inc.
Xenetic Biosciences, Inc.
HPV Vaccines Industry Developments
February 2020:Abbott launched a new quadrivalent and sub-unit vaccine. The vaccine launched can protect against four viral influenza strains. The product launch boosted the company's product portfolio and allowed it to generate more revenue.
Quadrivalent HPV Vaccines
Bivalent HPV Vaccines
Nonavalent HPV Vaccines
Girls & Women
Boys & Men
Hospitals
Clinics
Doctors’ Offices
Schools
Middle East and Africa
GCC Countries
Saudi Arabia
Iran
Rest of Middle East and Africa
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.095 Billion |
| Market Size 2023 | USD 0.098 Billion |
| Market Size 2032 | USD 0.13 Billion |
| Compound Annual Growth Rate (CAGR) | 3.80% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Market Competitive Landscape, Revenue Forecast, Growth Factors, and Trends |
| Segments Covered | Vaccine Type, Target Population, End-User and Region |
| Region Covered | Middle East and Africa |
| Countries Covered | GCC Countries, Saudi Arabia, Iran, and the Rest of the Middle East and Africa |
| Key Companies Profiled | Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc, Sanofi S.A., Bharat Biotech, Inovio Pharmaceuticals, Inc., and Xenetic Biosciences, Inc. |
| Key Market Opportunities | Â Rising prevalence of HPV-related diseases |
| Key Market Dynamics | Rising initiatives by the government to fund the HPV vaccines |
Frequently Asked Questions (FAQ) :
The Middle East and Africa HPV vaccines market size was valued at USD 0.095 Billion in 2022.
The market is expected to extend at a CAGR of 3.80% during the forecast period, 2024-2032.
The key players in the market are Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc, Sanofi S.A., Bharat Biotech, Inovio Pharmaceuticals, Inc., and Xenetic Biosciences, Inc.
The bivalent HPV vaccines category dominated the HPV vaccines market in 2022.
The women & girls category dominated the HPV vaccine market in 2022.
The hospital's category dominated the HPV vaccine market in 2022.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
